Linked Life Data

8563521

Source:http://linkedlifedata.com/resource/pubmed/id/8563521

Statements in which the resource exists as a subject.
PredicateObject
rdf:type
lifeskim:mentions
pubmed:issue
3
pubmed:dateCreated
1996-3-1
pubmed:abstractText
The high incidence of breast cancer in young women, and the unfavorable prognosis for those who present with a high number of lymph nodes involved with cancer, has encouraged the development and evaluation of new treatment strategies. The use of dose intensification is supported by laboratory and clinical models. In this review article, the use of dose intensification supported by hemopoietic growth factors, and also by hemopoietic stem cells, is discussed. The results of published studies of high-dose chemotherapy in Stage II, III, and IV breast cancer are discussed and summarized, including those randomized comparisons with more conventional therapy. Improvements in supportive care continue to reduce the risks from neutropenia and thrombocytopenia, and these and other toxicities are likely to decrease as side-effects are anticipated and experience increases.
pubmed:grant
pubmed:language
eng
pubmed:journal
pubmed:citationSubset
IM
pubmed:chemical
pubmed:status
MEDLINE
pubmed:month
Sep
pubmed:issn
0268-960X
pubmed:author
pubmed:issnType
Print
pubmed:volume
9
pubmed:owner
NLM
pubmed:authorsComplete
Y
pubmed:pagination
191-200
pubmed:dateRevised
2007-11-15
pubmed:meshHeading
pubmed:year
1995
pubmed:articleTitle
High-dose therapy for breast cancer.
pubmed:affiliation
Columbia University College of Physicians and Surgeons, New York, NY, USA.
pubmed:publicationType
Journal Article, Research Support, U.S. Gov't, P.H.S., Review